Uso de estatinas y el riesgo de Diabetes Mellitus tipo 2: Revisión basada en evidencias
DOI:
https://doi.org/10.5712/rbmfc11(38)1178Palabras clave:
Diabetes Mellitus, Tipo 2. Inhibidores de Hidroximetilglutaril-CoA Reductasas. IncidenciaResumen
Objetivo: Determinar la relación entre el uso de estatinas y la incidencia de Diabetes Mellitus tipo 2. Métodos: Se realizaron encuestas en las bases de datos de National Guidelines Clearinghouse, Cochrane Lybrary, Trip database, PubMed y MedLine utilizando los términos MeSH “diabetes mellitus type 2” y “Hidroximetilglutaril-CoA reductase Innibitors”. Se incluyeron revisiones sistemáticas, meta-análisis y ensayos controlados aleatorios para evaluar la incidencia de diabetes tipo 2 en los usuarios de estatinas en comparación con el placebo. Resultados: Se seleccionaron 10 artículos (1 meta-análisis y 9 ensayos controlados aleatorios). La evidencia sugiere que el uso de estatinas está asociado con un aumento de la incidencia de la diabetes tipo 2, especialmente con dosis más altas, en comparación con el placebo en la mayoría de los estudios evaluados. Conclusión: El riesgo de incidencia de diabetes tipo 2 debe considerarse especialmente al prescribir estatinas a los pacientes con riesgo cardiovascular bajo (SOR A), aunque los estudios seleccionados presentan algunas limitaciones (metodología heterogénea, siendo la mayor parte de los estudios observacionales).
Descargas
Métricas
Citas
Waters DD, Ho JE, DeMicco DA, Breazna A, Arsenault BJ, Wun CC, et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol. 2011;57(14):1535-45. DOI: http://dx.doi.org/10.1016/j.jacc.2010.10.047 DOI: https://doi.org/10.1016/j.jacc.2010.10.047
Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735-42. DOI: http://dx.doi.org/ 10.1007/s00125-014-3409-3.
Baker WL, Talati R, White CM, Coleman CI. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2010;87(1):98-107. DOI: http://dx.doi.org/10.1016/j.diabres.2009.10.008 DOI: https://doi.org/10.1016/j.diabres.2009.10.008
Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM. 2011;104(2):109-24. DOI: http://dx.doi.org/10.1093/qjmed/hcq165 DOI: https://doi.org/10.1093/qjmed/hcq165
Ebell MH, Siwek J, Weiss BD, Woolf SH, Susman J, Ewigman B, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. Am Fam Physician. 2004;69(3):548-56. PMID: 14971837 DOI: http://dx.doi.org/10.3122/jabfm.17.1.59 DOI: https://doi.org/10.3122/jabfm.17.1.59
Navarese EP, Buffon A, Andreotti F, Kozinski M, Welton N, Fabiszak T, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol. 2013;111(8):1123-30. DOI: http://dx.doi.org/10.1016/j.amjcard.2012.12.037 DOI: https://doi.org/10.1016/j.amjcard.2012.12.037
Jick SS, Bradbury BD. Statins and newly diagnosed diabetes. Br J Clin Pharmacol. 2004;58(3):303-9. DOI: http://dx.doi.org/10.1111/j.1365-2125.2004.02142.x DOI: https://doi.org/10.1111/j.1365-2125.2004.02142.x
Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women’s Health Initiative. Arch Intern Med. 2012;172(2):144-52. DOI: http://dx.doi.org/10.1001/archinternmed.2011.625 DOI: https://doi.org/10.1001/archinternmed.2011.625
Wang KL, Liu CJ, Chao TF, Huang CM, Wu CH, Chen SJ, et al. Statins, risk of diabetes, and implications on outcomes in the general population. J Am Coll Cardiol. 2012;60(14):1231-8. DOI: http://dx.doi.org/10.1016/j.jacc.2012.05.019 DOI: https://doi.org/10.1016/j.jacc.2012.05.019
Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013;346:f2610. DOI: http://dx.doi.org/10.1136/bmj.f2610 DOI: https://doi.org/10.1136/bmj.f2610
Danaei G, García Rodríguez LA, Fernandez Cantero O, Hernán MA. Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival. Diabetes Care. 2013;36(5):1236-40. DOI: http://dx.doi.org/10.2337/dc12-1756 DOI: https://doi.org/10.2337/dc12-1756
Chen CW, Chen TC, Huang KY, Chou P, Chen PF, Lee CC. Differential impact of statin on new-onset diabetes in different age groups: a population-based case-control study in women from an asian country. PLoS One. 2013;8(8):e71817. DOI: http://dx.doi.org/10.1371/journal.pone.0071817 DOI: https://doi.org/10.1371/journal.pone.0071817
Ko DT, Wijeysundera HC, Jackevicius CA, Yousef A, Wang J, Tu JV. Diabetes mellitus and cardiovascular events in older patients with myocardial infarction prescribed intensive-dose and moderate-dose statins. Circ Cardiovasc Qual Outcomes. 2013;6(3):315-22. DOI: http://dx.doi.org/10.1161/CIRCOUTCOMES.111.000015 DOI: https://doi.org/10.1161/CIRCOUTCOMES.111.000015
Dormuth CR, Filion KB, Paterson JM, James MT, Teare GF, Raymond CB, et al.; Canadian Network for Observational Drug Effect Studies Investigators. Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases. BMJ. 2014;348:g3244. DOI: http://dx.doi.org/10.1136/bmj.g3244 DOI: https://doi.org/10.1136/bmj.g3244
Macedo AF, Douglas I, Smeeth L, Forbes H, Ebrahim S. Statins and the risk of type 2 diabetes mellitus: cohort study using the UK clinical practice pesearch datalink. BMC Cardiovasc Disord. 2014;14:85. DOI: http://dx.doi.org/10.1186/1471-2261-14-85 DOI: https://doi.org/10.1186/1471-2261-14-85
Koh KK, Lim S, Sakuma I, Quon MJ. Caveats to aggressive lowering of lipids by specific statins. Int J Cardiol. 2012;154(2):97-101. DOI: http://dx.doi.org/10.1016/j.ijcard.2011.09.002 DOI: https://doi.org/10.1016/j.ijcard.2011.09.002
Sampson UK, Linton MF, Fazio S. Are statins diabetogenic? Curr Opin Cardiol. 2011;26(4):342-7. DOI: http://dx.doi.org/10.4093/dmj.2013.37.6.415. DOI: https://doi.org/10.4093/dmj.2013.37.6.415
Goldfine AB. Statins: is it really time to reassess benefits and risks? N Engl J Med. 2012;366(19):1752-5. DOI: http://dx.doi.org/10.14496/dia.41040851167.17. DOI: https://doi.org/10.14496/dia.41040851167.17
Pani LN, Nathan DM, Grant RW. Clinical predictors of disease progression and medication initiation in untreated patients with type 2 diabetes and A1C less than 7%. Diabetes Care. 2008;31(3):386-90. DOI: http://dx.doi.org/10.2337/dc07-1934 DOI: https://doi.org/10.2337/dc07-1934
Nichols GA, Hillier TA, Brown JB. Progression from newly acquired impaired fasting glusose to type 2 diabetes. Diabetes Care. 2007;30(2):228-33. DOI: http://dx.doi.org/10.2337/dc09-0896. DOI: https://doi.org/10.2337/dc09-0896
Fonseca VA. Defining and characterizing the progression of type 2 diabetes. Diabetes Care. 2009;32 Suppl 2:S151-6. DOI: http://dx.doi.org/10.2337/dc09-S301 DOI: https://doi.org/10.2337/dc09-S301
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Al enviar un manuscrito al RBMFC, los autores conservan la propiedad de los derechos de autor del artículo y autorizan a RBMFC a publicar ese manuscrito bajo la licencia Creative Commons Attribution 4.0 e identificarse como el vehículo de su publicación original.
